U.S. Markets open in 3 hrs 7 mins

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Trading At A 49.98% Discount

David Owens

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as an investment opportunity by projecting its future cash flows and then discounting them to today’s value. I will be using the Discounted Cash Flows (DCF) model. It may sound complicated, but actually it is quite simple! Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. Please also note that this article was written in February 2019 so be sure check out the updated calculation by following the link below.

Check out our latest analysis for Iovance Biotherapeutics

What’s the value?

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second ‘steady growth’ period. In the first stage we need to estimate the cash flows to the business over the next five years. For this I used the consensus of the analysts covering the stock, as you can see below. The sum of these cash flows is then discounted to today’s value.

5-year cash flow forecast

2019 2020 2021 2022 2023
Levered FCF ($, Millions) $-105.70 $-134.80 $-155.17 $238.00 $398.90
Source Analyst x1 Analyst x1 Est @ 15.11% Analyst x1 Analyst x1
Present Value Discounted @ 12.28% $-94.14 $-106.93 $-109.63 $149.75 $223.54

Present Value of 5-year Cash Flow (PVCF)= US$63m

After calculating the present value of future cash flows in the intial 5-year period we need to calculate the Terminal Value, which accounts for all the future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at an annual growth rate equal to the 10-year government bond rate of 2.7%. We discount this to today’s value at a cost of equity of 12.3%.

Terminal Value (TV) = FCF2023 × (1 + g) ÷ (r – g) = US$399m × (1 + 2.7%) ÷ (12.3% – 2.7%) = US$4.3b

Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = US$4.3b ÷ ( 1 + 12.3%)5 = US$2.4b

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is US$2.5b. In the final step we divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) or ADR then we use the equivalent number. This results in an intrinsic value of $20.03. Relative to the current share price of $10.02, the stock is quite undervalued at a 50% discount to what it is available for right now.

NASDAQGM:IOVA Intrinsic Value Export February 5th 19

Important assumptions

I’d like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don’t agree with my result, have a go at the calculation yourself and play with the assumptions. Because we are looking at Iovance Biotherapeutics as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 12.3%, which is based on a levered beta of 1.314. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For IOVA, I’ve compiled three fundamental aspects you should further research:

  1. Financial Health: Does IOVA have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does IOVA’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of IOVA? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow for every stock on the NASDAQ every 6 hours. If you want to find the calculation for other stocks just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.